Zephyr支气管内活瓣治疗异质性肺气肿的多中心随机对照试验(LIBERATE)
LIBERATE试验在24个中心纳入190例侧支通气极少或无的异质性肺气肿患者,按2:1随机接受Zephyr EBV或标准治疗。12个月时EBV组FEV1改善≥15%的比例为47.7%,SoC组为16.8%(P<0.001)。EBV在肺功能、运动耐量、呼吸困难和生活质量方面带来临床获益,气胸为最常见严重不良事件(26.6%)。
要点
- EBV组12个月FEV1改善≥15%者占47.7%,显著高于SoC组的16.8%。
- EBV组FEV1绝对值增加0.106 L,6分钟步行距离增加39.31 m,SGRQ降低7.05分。
- 治疗期气胸发生率为26.6%(34/128),为最常见严重不良事件。
核心结论
- Zephyr EBV在目标肺叶侧支通气极少或无的异质性肺气肿患者中,至少12个月内提供肺功能、运动耐量、呼吸困难和生活质量的临床获益,安全性可接受。
研究设计与样本
- 多中心随机对照试验,24个中心,2:1随机分配至EBV组(128例)或标准治疗组(62例),共190例。
- 主要终点为12个月时FEV1较基线改善≥15%的受试者比例(EBV与SoC的差异)。
主要发现
- 12个月时EBV组47.7%、SoC组16.8%的受试者FEV1改善≥15%(P<0.001)。
- 12个月EBV-SoC差异:FEV1 0.106 L(P<0.001);6分钟步行距离+39.31 m(P=0.002);SGRQ -7.05分(P=0.004)。
- 残余容积-522 ml(P<0.001)、mMRC呼吸困难评分-0.8分(P<0.001)、BODE指数-1.2分。
- 治疗期(操作至45天)气胸为最常见严重不良事件,EBV组34/128(26.6%)。
- EBV组治疗期死亡4例;46天至12个月期间EBV组和SoC组各死亡1例。
临床怎么用
- 对于目标肺叶侧支通气极少或无的异质性肺气肿患者,可考虑Zephyr EBV治疗以改善肺功能、运动耐量、呼吸困难和生活质量。
- 治疗期需警惕气胸风险(26.6%),应做好监测与处理准备。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
RATIONALE: This is the first multicenter randomized controlled trial to evaluate the effectiveness and safety of Zephyr Endobronchial Valve (EBV) in patients with little to no collateral ventilation out to 12 months. OBJECTIVES: To evaluate the effectiveness and safety of Zephyr EBV in heterogeneous emphysema with little to no collateral ventilation in the treated lobe. METHODS: Subjects were enrolled with a 2:1 randomization (EBV/standard of care [SoC]) at 24 sites. Primary outcome at 12 months was the ΔEBV-SoC of subjects with a post-bronchodilator FEV1 improvement from baseline of greater than or equal to 15%. Secondary endpoints included absolute changes in post-bronchodilator FEV1, 6-minute-walk distance, and St. George's Respiratory Questionnaire scores. MEASUREMENTS AND MAIN RESULTS: A total of 190 subjects (128 EBV and 62 SoC) were randomized. At 12 months, 47.7% EBV and 16.8% SoC subjects had a ΔFEV1 greater than or equal to 15% (P < 0.001). ΔEBV-SoC at 12 months was statistically and clinically significant: for FEV1, 0.106 L (P < 0.001); 6-minute-walk distance, +39.31 m (P = 0.002); and St. George's Respiratory Questionnaire, -7.05 points (P = 0.004). Significant ΔEBV-SoC were also observed in hyperinflation (residual volume, -522 ml; P < 0.001), modified Medical Research Council Dyspnea Scale (-0.8 points; P < 0.001), and the BODE (body mass index, airflow obstruction, dyspnea, and exercise capacity) index (-1.2 points). Pneumothorax was the most common serious adverse event in the treatment period (procedure to 45 d), in 34/128 (26.6%) of EBV subjects. Four deaths occurred in the EBV group during this phase, and one each in the EBV and SoC groups between 46 days and 12 months. CONCLUSIONS: Zephyr EBV provides clinically meaningful benefits in lung function, exercise tolerance, dyspnea, and quality of life out to at least 12 months, with an acceptable safety profile in patients with little or no collateral ventilation in the target lobe. Clinical trial registered with www.clinicaltrials.gov (NCT 01796392).
引用
- Criner GJ, Sue R, Wright S, et al. A Multicenter Randomized Controlled Trial of Zephyr Endobronchial Valve Treatment in Heterogeneous Emphysema (LIBERATE). Am J Respir Crit Care Med. 2018. PMID: 29787288. doi:10.1164/rccm.201803-0590OC
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。